Pharmaceutical and biotech companies are looking for new ways to increase the efficiency of drug discovery process while minimising costs and time for approvals. Biomarkers are fast becoming an essential part of clinical development from discovery to approval. According to industry research, the global biomarker market is estimated to be $20.5 billion by 2014, growing at a CAGR of 19.7 %.
Additionally, the use of proteomics in biomarker testing and identification has boosted the services for biomarkers. A large number of companies now have commercialised biomarker tests employing a variety of technologies. However, there are several barriers and challenges that must be overcome behind these technologies.
Proud to present its 3rd Annual Biomarker Conference, which will be held in London UK on 23-24 March 2010.This conference will enable you to identify and overcome challenges on how to incorporate biomarkers into your discovery programs as well as highlighting new technologies and strategies to improved prevention and care approaches.
Conference Main Themes:
• Use of academic laboratories in clinical development to foster collaborative research 
• Biomarkers in Translational Medicine 
• Integration of a companion diagnostic strategy into oncology drug development 
• How biomarkers, personalized medicines, and pharmaceutical will interact and create value for patients? 
• Mass Spectrometry in Biomarker Discovery 
• New results in functional genomics 
• Anti-inflammatory efficacy of drug substances using biomarkers of inflammation
• Biomarker assay development and validation in cancer
• Role of biomarkers in the development of personalized medicine
• Biomarkers in a clinical perspective
• Development in protein array technologies for biomarker discovery